YP
PFE icon

Yellowstone Partners’s Pfizer PFE Stock Holding History

Yellowstone Partners’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$941K Sell
27,378
-29
-0.1% -$989 0.53% 44
2017
Q3 		$928K Buy
+27,407
New +$881K 0.49% 49
2016
Q3 		$1.54M Buy
48,077
+11,698
+32% +$391K 0.57% 40
2016
Q2 		$1.22M Sell
36,379
-1,553
-4% -$49.6K 0.52% 57
2016
Q1 		$1.07M Buy
37,932
+7,391
+24% +$211K 0.46% 59
2015
Q4 		$935K Buy
30,541
+3,191
+12% +$100K 0.42% 48
2015
Q3 		$815K Buy
27,350
+2,816
+11% +$90.3K 0.39% 50
2015
Q2 		$780K Buy
24,534
+8,813
+56% +$287K 0.35% 53
2015
Q1 		$519K Buy
15,721
+2,013
+15% +$64K 0.26% 73
2014
Q4 		$405K Buy
13,708
+1,979
+17% +$56.7K 0.22% 94
2014
Q3 		$329K Buy
11,729
+2,249
+24% +$63.1K 0.19% 107
2014
Q2 		$267K Buy
9,480
+2,677
+39% +$76.3K 0.16% 129
2014
Q1 		$207K Buy
+6,803
New +$203K 0.13% 148

Other funds holding PFE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Yellowstone Partners's PFE Position: Q4 2017 in Review

Yellowstone Partners reduced its Pfizer (PFE) stake by 0.11% in Q4 2017, selling an estimated $989 and leaving 27,378 shares worth $941K. The position accounts for 0.53% of the portfolio, ranked #44.

Yellowstone Partners first reported a position in PFE in Q1 2014 and has held it in 13 quarters since. The position peaked at $1.54M in Q3 2016. 2,243 funds tracked by Wall St. Rank hold PFE as of Q4 2017.

  • Yellowstone Partners held 27,378 shares of Pfizer worth $941K as of Q4 2017.
  • Yellowstone Partners sold 29 Pfizer shares in Q4 2017, an estimated $989.
  • Pfizer made up 0.53% of Yellowstone Partners's portfolio in Q4 2017, its #44 holding.
  • Yellowstone Partners first reported a position in Pfizer in Q1 2014 and has held it in 13 quarters since.
  • Yellowstone Partners's Pfizer position peaked at $1.54M in Q3 2016.
  • 2,243 funds tracked by Wall St. Rank held Pfizer as of Q4 2017.

Based on Yellowstone Partners's 13F filing for Q4 2017, filed 24 Jan 2018.